Antheia Secures $17 Million to Boost U.S. Production of Critical Pharmaceutical Ingredients
![](https://antheia.bio/wp-content/uploads/2024/07/Christina-Smolke-at-SynBioBeta2023-1.png)
Antheia, a pioneering pharmaceutical ingredient manufacturer, has announced a significant $17 million funding boost aimed at transforming the supply chains of essential medicines.
Antheia secures new funding to boost pharmaceutical ingredients production
![](https://antheia.bio/wp-content/uploads/2024/07/james-coleman-IMe6fLWEu6E-unsplash-1.png)
The company secured funding through government project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), alongside strategic investment from In-Q-Tel and Echo
Secretary of State Antony Blinken visits the Bay Area
![SOS-visit](https://antheia.bio/wp-content/uploads/2024/05/SOS-visit-thumbnail.png)
Antony Blinken tours Antheia biotech lab, emphasizing its potential to address nationwide medicine shortages by overcoming supply chain issues with advanced bio-technology
Chemicals Knowledge Hub: DCAT Week 2024 Andrea Conforto, VP/Biotech for CDMO at Olon and Zack McGahey, COO at Antheia
![Antheia-x-Olon](https://antheia.bio/wp-content/uploads/2024/05/Antheia-x-Olon-thumbnail.png)
In this interview with Antheia and Olon, two leading companies in the life sciences industry, we discussed their ongoing partnership, market trends, and the future of the industry.
PharmaSource: Antheia and Olon Extend Biomanufacturing Partnership
![Olon-partnership](https://antheia.bio/wp-content/uploads/2024/05/Olon-partnership-thumbnail.png)
Antheia and Olon have announced a continuation of partnership, leveraging Olon’s fermentation infrastructure for the manufacture of Antheia’s early products
Antheia and Olon Continue Partnership for Biomanufacturing Antheia’s Pipeline of KSMs and APIs for Essential Medicines
![Press-Release-Thumbnail](https://antheia.bio/wp-content/uploads/2024/01/Press-Release-Thumbnail_Compressed-1024x768.webp)
Antheia and Olon established this partnership in 2022 to leverage Olon’s fermentation sites across Italy. Olon has since played a pivotal role as a CDMO for scaling Antheia’s biomanufacturing processes and producing its Biosynthetic KSMs (key starting materials) and APIs.
Antheia Achieves Major Commercial Milestone
![Press-Release-Thumbnail](https://antheia.bio/wp-content/uploads/2024/01/Press-Release-Thumbnail_Compressed-1024x768.webp)
Company’s first full-scale fermentation run reinforces commercial viability for a robust pipeline of Biosynthetic KSMS and APIs
Introducing Antheia’s Reinvigorated Brand Identity
![](https://antheia.bio/wp-content/uploads/2023/06/Antheia-Menlo-Park-HQ-jpg.webp)
Since launching Antheia in 2015, we’ve made tremendous strides toward our mission to transform pharmaceutical supply chains for essential medicines. We’ve strengthened our leadership team with veteran executives across R&D, operations, supply chain, and quality and regulatory, we’ve repeatedly validated our technology at commercially-relevant scales, and we are now actively moving into full-scale production to bring our products to market.
Leveraging Synthetic Biology for Resilient Pharma Supply Chains and Accessible Medicines
![](https://antheia.bio/wp-content/uploads/2023/05/Leveraging-Synthetic-Biology-for-Resilient-Pharma-Supply-Chains-and-Accessible-Medicines.png)
Antheia was founded in 2015 by Dr. Christina Smolke, CEO and Dr. Kristy Hawkins, CSO and is based in Menlo Park, California. Antheia’s co-founders are pioneers in the fields of synthetic biology and metabolic engineering and are applying these technologies to transform pharmaceutical supply chains in order to better support the needs of 21st century healthcare.
Live at SynBioBeta
![](https://antheia.bio/wp-content/uploads/2023/06/SynBioBeta-jpg.webp)
Each year, SynBioBeta hosts the The Global Synthetic Biology Conference to showcase the latest cutting-edge developments in biology that are changing how we solve global problems. As a proud sponsor of this year’s event, we look forward to connecting with the synthetic biology community and sharing our progress toward transforming pharmaceutical supply chains.